Immunogenicity of a public neoantigen derived from mutated PIK3CA
S. S. Chandran, J. Ma, M. G. Klatt, F. Dundar, C. Bandlamudi, P. C. Razavi, H. Y. Wen, B. Weigelt, P. Zumbo, S. N. Fu, L. B. Banks, W. D. Bestman, A. Drilon, D. Betel, D. A. Scheinberg, , C. A. Klebanoff
The paper investigates the immunogenicity of a public neoantigen derived from mutated PIK3CA, showing it is recognized by T cells and presents a framework for immunotherapy.
bioRxiv · Apr 8, 2021 · PreprintImmunology